Kyverna Therapeutics, INC. (KYTX) — SEC Filings

Q: What are the key financial highlights for Kyverna Therapeutics, INC.?

Key financial highlights for Kyverna Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Kyverna Therapeutics, INC.?

Key executives at Kyverna Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Kyverna Therapeutics, INC. stock?

Risk factors for Kyverna Therapeutics, INC. (KYTX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Kyverna Therapeutics, INC.?

Forward-looking statements and predictions from Kyverna Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Kyverna Therapeutics, INC.. Recent 8-K filing on Apr 22, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Kyverna Therapeutics, INC. on SEC EDGAR

Overview

Kyverna Therapeutics, INC. (KYTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 22, 2026: Kyverna Therapeutics, Inc. filed an 8-K on April 22, 2026, primarily for Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes an exhibit (EX-99.1) which contains various graphic files, suggesting it may contain visual data or presentations related to the company's operatio

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 1 mixed. The dominant filing sentiment for Kyverna Therapeutics, INC. is neutral.

Filing Type Overview

Kyverna Therapeutics, INC. (KYTX) has filed 17 8-K, 1 DEFA14A, 1 EFFECT, 6 10-Q, 1 DEF 14A, 2 10-K, 5 SC 13G, 1 SC 13D, 2 S-1/A, 1 S-1 with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

Kyverna Therapeutics Files 8-K with Exhibits — 8-K · Apr 22, 2026 Risk: low
Kyverna Therapeutics, Inc. filed an 8-K on April 22, 2026, primarily for Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes an exhi
8-K Filing — 8-K · Apr 20, 2026
Kyverna Therapeutics Files DEFA14A Proxy Materials — DEFA14A · Apr 13, 2026 Risk: low
Kyverna Therapeutics, Inc. filed a DEFA14A on April 13, 2026, related to additional definitive proxy soliciting materials. The filing, with SEC Accession Number
EFFECT Filing — EFFECT · Apr 3, 2026
Kyverna Therapeutics Files 8-K: Material Definitive Agreement — 8-K · Dec 18, 2025 Risk: medium
On December 17, 2025, Kyverna Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
Kyverna Therapeutics Files 8-K — 8-K · Dec 15, 2025 Risk: low
Kyverna Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details th
Kyverna's Losses Widen Amid Soaring R&D Costs — 10-Q · Nov 12, 2025 Risk: high
Kyverna Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $123.5 million, up from $89.988 mi
8-K Filing — 8-K · Nov 3, 2025
Kyverna Therapeutics Files 8-K — 8-K · Oct 29, 2025 Risk: low
Kyverna Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
Kyverna Therapeutics Reports Director/Officer Changes & Financials — 8-K · Sep 25, 2025 Risk: medium
Kyverna Therapeutics, Inc. filed an 8-K on September 25, 2025, reporting events as of September 19, 2025. The filing pertains to the departure and election of d
Kyverna's Q2 Loss Widens on Soaring R&D for Autoimmune Therapies — 10-Q · Aug 12, 2025 Risk: high
Kyverna Therapeutics, Inc. (KYTX) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $86.7 million, up from $55.5 mill
Kyverna Therapeutics Files 8-K on Executive & Board Changes — 8-K · Jun 30, 2025 Risk: medium
Kyverna Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of cer
Kyverna Therapeutics Files 8-K on Shareholder Votes & Financials — 8-K · Jun 3, 2025 Risk: low
Kyverna Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The comp
Kyverna Therapeutics Files 10-Q Post-IPO — 10-Q · May 13, 2025 Risk: medium
Kyverna Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported research and development expenses for the first quarter of
Kyverna Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 14, 2025 Risk: low
Kyverna Therapeutics, Inc. filed its definitive proxy statement on April 14, 2025, for its annual meeting of stockholders. The filing covers the fiscal year end
10-K Filing — 10-K · Mar 27, 2025
Marinus to Acquire Kyverna Therapeutics for $550M — 8-K · Jan 21, 2025 Risk: medium
Kyverna Therapeutics, Inc. announced on January 21, 2025, that it has entered into a definitive agreement to be acquired by Marinus Pharmaceuticals, Inc. The tr
Kyverna Therapeutics Files 8-K Report — 8-K · Jan 13, 2025 Risk: low
On January 13, 2025, Kyverna Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD
Kyverna Therapeutics Appoints New CMO and CFO — 8-K · Nov 26, 2024 Risk: low
Kyverna Therapeutics, Inc. announced on November 26, 2024, that its Board of Directors appointed Dr. Michael J. Ybarra as Chief Medical Officer, effective Novem
Kyverna Therapeutics Q3 2024 Update — 10-Q · Nov 13, 2024 Risk: medium
Kyverna Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter
SC 13G Filing — SC 13G · Nov 12, 2024
Kyverna Therapeutics Appoints New Chief Medical Officer — 8-K · Oct 21, 2024 Risk: medium
Kyverna Therapeutics, Inc. announced on October 21, 2024, that its Board of Directors has appointed Dr. Michael J. Ybarra as Chief Medical Officer, effective Oc
SC 13G Filing — SC 13G · Oct 10, 2024
Kyverna Therapeutics Appoints New Chief Medical Officer — 8-K · Sep 16, 2024 Risk: medium
Kyverna Therapeutics, Inc. announced on September 13, 2024, the appointment of Dr. Michael J. Ybarra as Chief Medical Officer. Dr. Ybarra brings extensive exper
Kyverna Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
Kyverna Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial status, including details on its cash, investm
Kyverna Therapeutics Files 8-K — 8-K · Jul 15, 2024 Risk: low
On July 15, 2024, Kyverna Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific fina
8-K Filing — 8-K · Jun 14, 2024
Kyverna Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
Kyverna Therapeutics, Inc. (KYTX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Kyverna Therapeutics, Inc. filed a 10-Q for the period ending Ma
Vida Ventures Acquires Stake in Kyverna Therapeutics — SC 13D · May 3, 2024 Risk: medium
Vida Ventures, LLC, along with its affiliates Fred Cohen, Vida Ventures GP III, L.L.C., Vida Ventures III, L.P., Vida Ventures III-A, L.P., and VV Manager LLC,
Kyverna Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024 Risk: low
Kyverna Therapeutics, Inc. (KYTX) filed a Annual Report (10-K) with the SEC on March 26, 2024. Kyverna Therapeutics, Inc. filed its annual report on Form 10-K f
SC 13G Filing — SC 13G · Feb 22, 2024
SC 13G Filing — SC 13G · Feb 20, 2024
SC 13G Filing — SC 13G · Feb 14, 2024
Kyverna Opts Out of EGC Accounting Transition Period — 8-K · Feb 12, 2024 Risk: low
Kyverna Therapeutics, Inc. filed an 8-K on February 12, 2024, to report that it is an "emerging growth company" and has elected not to use the extended transiti
Kyverna Therapeutics Files Amendment to S-1 Registration Statement — S-1/A · Feb 6, 2024 Risk: low
Kyverna Therapeutics, Inc. (KYTX) filed a Amended IPO Registration (S-1/A) with the SEC on February 6, 2024. Kyverna Therapeutics, Inc. filed an amendment (S-1/
Kyverna Therapeutics Files Amendment to S-1 Registration Statement — S-1/A · Feb 1, 2024 Risk: low
Kyverna Therapeutics, Inc. (KYTX) filed a Amended IPO Registration (S-1/A) with the SEC on February 1, 2024. Kyverna Therapeutics, Inc. filed an amendment (S-1/
Kyverna Therapeutics Files S-1 for Public Offering — S-1 · Jan 16, 2024 Risk: low
Kyverna Therapeutics, Inc. (KYTX) filed a IPO Registration (S-1) with the SEC on January 16, 2024. Kyverna Therapeutics, Inc. filed an S-1 registration statemen

Risk Profile

Risk Assessment: Of KYTX's 27 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Kyverna Therapeutics, INC.'s most recent 10-Q filing (Nov 12, 2025):

Revenue: Not Disclosed
Net Income: -$123.5M
EPS: Not Disclosed
Debt-to-Equity: Not Disclosed
Cash Position: $34.164M
Operating Margin: Not Disclosed
Total Assets: $187.156M
Total Debt: Not Disclosed

Key Executives

Dr. Michael J. Ybarra
Ms. Jennifer L. Jones
Ryan Jones
Fred Cohen
Jean-Philippe Kouakou-Zebouah
Peter Maag, Ph.D.

Industry Context

Kyverna Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on cell therapies for autoimmune diseases. This field is characterized by rapid innovation, significant R&D investment, and lengthy, expensive clinical trial processes. Key trends include the development of targeted therapies and the increasing complexity of manufacturing advanced biologics.

Top Tags

Biotechnology (7) · Kyverna Therapeutics (5) · 10-Q (4) · IPO (4) · biotech (4) · disclosure (3) · 8-k (3) · corporate-governance (3) · executive-appointment (3) · sec-filing (2)

Key Numbers

SEC Accession Number: 0001193125-26-152870 — Unique identifier for this specific filing
Filing Date: 2026-04-13 — Date the filing was accepted by the SEC
Commission File Number: 001-41947 — SEC File Number for Kyverna Therapeutics
IRS Employer Identification No.: 83-1365441 — EIN for Kyverna Therapeutics
Net Loss: $123.5M — for the nine months ended September 30, 2025, up from $89.988M in 2024
Research and Development Expenses: $103.706M — for the nine months ended September 30, 2025, a 31.3% increase from $78.990M in 2024
Cash and Cash Equivalents: $34.164M — as of September 30, 2025, down from $96.621M at December 31, 2024
Accumulated Deficit: $387.0M — as of September 30, 2025
New Funding: $25.0M — secured from Oxford Finance LLC in October 2025
Common Stock Shares Outstanding: 43,796,170 — as of October 31, 2025
SEC File Number: 001-41947 — Identifies the company's filing record with the SEC.
Cash and Marketable Securities: $211.7M — as of June 30, 2025, down from $285.4M at Dec 31, 2024
Common Shares Outstanding: 43,245,667 — as of August 4, 2025
Net Loss Per Share: $0.97 — for three months ended June 30, 2025, up from $0.67 in 2024
Reporting Period End Date: 2025-03-31 — Indicates the period covered by the 10-Q filing.

Forward-Looking Statements

{"claim":"Kyverna Therapeutics, Inc. will likely incur higher accounting and compliance costs in the near term due to its election.","entity":"Kyverna Therapeutics, Inc.","targetDate":"2024-12-31","confidence":"medium"}
{"claim":"The company's financial statements will reflect new accounting standards sooner than if they had utilized the extended transition period.","entity":"Kyverna Therapeutics, Inc.","targetDate":"2025-01-01","confidence":"high"}

Related Companies

KYRN · MRNS · KYVR · NTLA

Frequently Asked Questions

What are the latest SEC filings for Kyverna Therapeutics, INC. (KYTX)?

Kyverna Therapeutics, INC. has 37 recent SEC filings from Jan 2024 to Apr 2026, including 17 8-K, 6 10-Q, 5 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of KYTX filings?

Across 37 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Kyverna Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Kyverna Therapeutics, INC. (KYTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Kyverna Therapeutics, INC.?

Key financial highlights from Kyverna Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for KYTX?

The investment thesis for KYTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Kyverna Therapeutics, INC.?

Key executives identified across Kyverna Therapeutics, INC.'s filings include Dr. Michael J. Ybarra, Ms. Jennifer L. Jones, Ryan Jones, Fred Cohen, Jean-Philippe Kouakou-Zebouah and 1 others.

What are the main risk factors for Kyverna Therapeutics, INC. stock?

Of KYTX's 27 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 14 low-risk.

What are recent predictions and forward guidance from Kyverna Therapeutics, INC.?

Recent forward-looking statements from Kyverna Therapeutics, INC. include guidance on {"claim":"Kyverna Therapeutics, Inc. will likely incur higher accounting and compliance costs in the near term due to it and 1 other predictions.